 MaxCyte Inc AIM:MXCT said it signed a strategic platform license SPL for its Flow Electroporation technology and ExPERT platform with Vertex Pharmaceuticals NASDAQ:VRTX, a biotechnology company. The AIM-listed company will receive platform licensing fees and program-related revenue from the gene editing therapy through the agreement, it said. 